Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

FDA Issues Final Guidance on Submitting ANDAs, Highlighting Recurring Deficiencies

  • Post author:PacConAdmin
  • Post published:January 26, 2022
  • Post category:Drug Industry Daily

The FDA, as part of its Drug Competition Action Plan, has released final guidance for companies preparing to submit abbreviated new drug applications (ANDAs) to the agency for generic products.…

Continue ReadingFDA Issues Final Guidance on Submitting ANDAs, Highlighting Recurring Deficiencies

Aurobindo Facility in India Draws FDA Warning Letter India

  • Post author:PacConAdmin
  • Post published:January 26, 2022
  • Post category:Drug Industry Daily

The FDA issued a warning letter to Aurobindo Pharmaceutical after an inspection of the company’s active pharmaceutical ingredient (API) facility in Hyderabad, India. Source: Drug Industry Daily

Continue ReadingAurobindo Facility in India Draws FDA Warning Letter India

Sponsors Still Sluggish to Report Clinical Trial Results, Analysis Finds

  • Post author:PacConAdmin
  • Post published:January 26, 2022
  • Post category:Drug Industry Daily

A number of sponsors, including some prominent U.S. hospital systems and universities, are still skimping on reporting their trial results as required by federal law, a new analysis shows. Source:…

Continue ReadingSponsors Still Sluggish to Report Clinical Trial Results, Analysis Finds

FDA Orders Clinical Hold on Five Trials of Gilead’s Checkpoint Inhibitor Magrolimab

  • Post author:PacConAdmin
  • Post published:January 26, 2022
  • Post category:Drug Industry Daily

The FDA has placed a clinical hold that affects five trials of Gilead Sciences’ investigational blood cancer drug, which it just acquired two years ago. Source: Drug Industry Daily

Continue ReadingFDA Orders Clinical Hold on Five Trials of Gilead’s Checkpoint Inhibitor Magrolimab

Pfizer Urged to Make Paxlovid Available Beyond North America and Europe

  • Post author:PacConAdmin
  • Post published:January 25, 2022
  • Post category:Drug Industry Daily

Pfizer is coming under increasing pressure to make its highly effective COVID-19 antiviral treatment Paxlovid more accessible to countries beyond those in North America and Europe. Source: Drug Industry Daily

Continue ReadingPfizer Urged to Make Paxlovid Available Beyond North America and Europe

FDA Issues New Guidance on Updating Labeling for Generics After Revisions to Reference Drug Labels

  • Post author:PacConAdmin
  • Post published:January 25, 2022
  • Post category:Drug Industry Daily

The FDA has released draft guidance for applicants and holders of an abbreviated new drug application (ANDA) on updating their labeling after revisions to the approved labeling of a reference…

Continue ReadingFDA Issues New Guidance on Updating Labeling for Generics After Revisions to Reference Drug Labels

Eli Lilly Gets Strongly Worded Untitled Letter From FDA About Trulicity Instagram Ad

  • Post author:PacConAdmin
  • Post published:January 25, 2022
  • Post category:Drug Industry Daily

The FDA has slapped Eli Lilly with an Untitled Letter over what it calls a “misleading” and “particularly concerning” ad the company posted on Instagram for its type 2 diabetes…

Continue ReadingEli Lilly Gets Strongly Worded Untitled Letter From FDA About Trulicity Instagram Ad

FDA Issues Draft Guidance on Requirements Around Collecting and Providing Samples

  • Post author:PacConAdmin
  • Post published:January 25, 2022
  • Post category:Drug Industry Daily

The FDA has issued draft guidance clarifying the regulatory requirements for collecting and providing portions of official samples of drugs, foods or cosmetics that may be needed for the agency’s…

Continue ReadingFDA Issues Draft Guidance on Requirements Around Collecting and Providing Samples

Sanofi Teams Up With UK Startup to Test New Treatments

  • Post author:PacConAdmin
  • Post published:January 24, 2022
  • Post category:Drug Industry Daily

Sanofi is partnering with Protas, a new UK-based nonprofit organization masterminded by Martin Landray, the leader of the UK’s lauded and highly successful RECOVERY trial, which evaluated multiple treatments for…

Continue ReadingSanofi Teams Up With UK Startup to Test New Treatments

Gilead Pulls Zydelig Blood Cancer Indications Over Lack of Confirmatory Trials

  • Post author:PacConAdmin
  • Post published:January 24, 2022
  • Post category:Drug Industry Daily

Gilead Sciences has yanked two blood cancer approvals for Zydelig (idelalisib) over its failure to conduct FDA-required confirmatory trials. Source: Drug Industry Daily

Continue ReadingGilead Pulls Zydelig Blood Cancer Indications Over Lack of Confirmatory Trials
  • Go to the previous page
  • 1
  • …
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • …
  • 385
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.